Top 3 Health Care Stocks That May Crash In Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Source: Benzinga
Overbought Stocks in Healthcare: As of April 7, 2025, three healthcare stocks—Alumis Inc, Chimerix Inc, and Journey Medical Corp—are identified as overbought based on their high RSI values, indicating potential risk for investors focused on momentum trading.
Recent Developments: Alumis has entered a licensing agreement with Kaken Pharmaceuticals, Chimerix reported quarterly losses that beat expectations, and Journey Medical appointed a new COO, all contributing to significant stock price increases in recent months.
Analyst Views on DERM
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
